


## Discontinuation of Isolation for Inpatients Infected by SARS-CoV-2




Discontinuation of isolation for patients with **mild to moderate illness**

*All criteria must be satisfied before isolation is discontinued:*



10

- A. **10 days** have passed since the onset of symptoms or time of diagnosis (whichever period is longer), and
- B. There has been **improvement in respiratory symptoms** (e.g., cough, shortness of breath), and
- C. At least **24 hours** have passed since resolution of fever, if any (without the use of antipyretics)


Discontinuation of isolation for persons with **severe to critical illness\*** or who are **severely immunocompromised\*\***

*All criteria must be satisfied before isolation is discontinued:*



20

- A. **20 days** have passed since the onset of symptoms or time of diagnosis (whichever period is longer), and
- B. There has been **improvement in respiratory symptoms** (e.g., cough, shortness of breath), and
- C. At least **24 hours** have passed since resolution of fever, if any (without the use of antipyretics)



If the above criteria are satisfied, isolation may be discontinued for all **acute-care patients and residents of the CLC** who are infected by SARS-CoV-2.



**\*Severe Illness:** Individuals who have respiratory frequency >30 breaths per minute, SpO<sub>2</sub> <94% on room air at sea level (or, for patients with chronic hypoxemia, a decrease from baseline of >3%), ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO<sub>2</sub>/FiO<sub>2</sub>) <300 mmHg, or lung infiltrates >50%.

**\*\*Immunocompromise:** For the purposes of this guidance, CDC used the following definitions:

- Being on chemotherapy for cancer
- Untreated HIV infection with CD4 T lymphocyte count < 200
- Combined primary immunodeficiency disorder
- Receipt of prednisone >20mg/day for more than 14 days.
- Other factors, such as advanced age, diabetes mellitus, or end-stage renal disease, may pose a much lower degree of immunocompromise and not clearly affect decisions about duration of Transmission-Based Precautions.